Portland, OR — 12/22/2017 — Atipamezole is a synthetic alpha 2 adrenergic receptor antagonist drug, which reverses the effects of sedative and analgesic drugs such as medetomidine, xylazine, amitraz, and detomidine among others, in animals. In addition, it is used to treat amitraz and imidazoline decongestants toxicity in animals.
Get sample copy @ https://www.alliedmarketresearch.com/request-toc-and-sample/3352
Reduction in sedative time of animals shortens the in-clinic stay, saves the time of the staff, reduces hospitalization costs, and reduces revisits of the animal owner. Furthermore, the rising pet ownership and increasing healthcare expenditure on animals are anticipated to fuel the market growth. However, adverse effects of atipamezole and stringent government regulations associated with the safety and efficacy of atipamezole is anticipated to hinder the market growth. For instance, atipamezole is not approved for use in cats in the U.S. Ongoing R&D activities on atipamezole is anticipated to provide opportunities for the market growth.
The market is segmented on the basis of application, route of administration, and geography. Based on application, the market is divided into anti-sedative and others (anti-analgesic and amitraz toxicity). By route of administration, the market is segmented into intravenous, intramuscular, and others (subcutaneous and intraperitoneal). Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Browse full report @ https://www.alliedmarketresearch.com/atipamezole-market
Latest posts by Sarah Thompson (see all)
- Year-End Report 2017, Heliospectra AB ( publ) - February 23, 2018
- The Future of Comics Starts Here! M2 releases groundbreaking digital comics platform: Macroverse - February 23, 2018
- Austin Startup a Mighty Force in Digital Design - February 23, 2018